Antisense restenosis composition and method

• US 20070265215A1
• Filed: 05/11/2006
• Published: 11/15/2007
• Est. Priority Date: 05/11/2006
• Status: Abandoned Application

• Current Assignee: Avi Biopharma, Inc.
• Original Assignee: Avi Biopharma, Inc.
• Inventors: Weller, Dwight, Iversen, Patrick
• Application Number:
  US11/433,308
• Publication Number:
  US 20070265215A1
• Time in Patent Office: Days
• US Class Current: 514/44.A
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/314 Phosphoramidates
• CPC Class Codes: C12N 2310/3233 Morpholino-type ring
• CPC Class Codes: C12N 2310/351 Conjugate
• CPC Class Codes: C12N 2320/30 Special therapeutic applications

Abstract

The present invention provides an improved method for reducing the risk or severity of restenosis following cardiac angioplasty. The method includes administering to a target vessel region, a morpholino antisense compound having a phosphorus-containing backbone linkages, and spanning the start codon of a human c-myc mRNA. Also disclosed are novel antisense compounds and compositions, and a method for assaying the effectiveness of antisense delivery and uptake to a target vessel region.

Claims

1. A method of reducing the risk of restenosis in a region of a patient'"'"'s coronary vessel which has been treated by coronary angioplasty using a catheter with a distal-end expandable balloon, or which is at a junction formed in a coronary bypass operation, said method comprising

administering to the patient, by local administration directly to the vessel site of injury, a morpholino antisense compound having from 8 to 40 morpholino subunits (a) including a targeting base sequence that is complementary to a target sequence of at least 12 contiguous bases within the AUG start site region of human c-myc mRNA defined by SEQ ID NO:

2, and (b) that are linked by uncharged phosphorodiamidate linkages interspersed with at least two and up to half positively charged phosphorodiamidate linkages, in an amount effective to reduce the risk of restenosis in the patient, where said administering is carried out by a mode of administration selected from the group consisting of

(a) contacting the region of the vessel with a reservoir containing the antisense compound, and introducing the compound from the reservoir into the vessel by iontophoresis or electroporation;

(b) injecting the compound from the catheter directly into the region of the vessel, under pressure, through injectors contained on the surface of the catheter balloon, where said injectors are capable of penetrating the tunica media in the vessel;

(c) injecting into or contacting the region of the vessel, microparticles containing the antisense compound in entrapped form;

(d) contacting the region of the vessel with a hydrogel coating contained on the surface of the catheter balloon, and containing the antisense compound is diffusable form; and

(e) contacting the region of the vessel with a stent having an outer surface layer containing the antisense compound in diffusable form.

2. The method of claim 1, wherein said morpholino subunits are joined by phosphorodiamidate linkages, in accordance with the structure:

3. The method of claim 1, wherein said antisense compound has a T_m, with respect to binding to said target sequence, of greater than about 50°

C., and said compound is actively taken up by mammalian cells.

4. The method of claim 1, wherein the antisense compound has a targeting sequence having at least 90% homology to the sequence identified by SEQ ID NOS. 1.

5. The method of claim 1, wherein the antisense compound has a targeting sequence having at least 90% homology to a sequence selected from SEQ ID NOS. 3 and 4.

6. The method of claim 1, wherein the amount of antisense compound administered is between about 0.5 and 20 mg.

7. The method of claim 1, for use in mode of administration (a), wherein the antisense compound is contained in a volume between two inflated balloons in the catheter, the compound contains a net charge, and the volume is subjected to pulsed electric fields effective to iontophoretically drive the compound into region of the vessel.

8. The method of claim 1, for use in mode of administration (a), wherein the antisense compound is contained in a volume between two inflated balloons in the catheter, and the volume is subjected to pulsed electric fields effective to facilitate compound uptake into vessel-region cells by electroporation.

9. The method of claim 1, for use in mode of administration (b), wherein the catheter balloon has a plurality of outer-facing channels that communicate with a distal-tip reservoir, each channel having one or more injection ports, and said injecting includes forcing a solution or suspension of the antisense compound from said reservoir through said injection ports when the balloon is in an inflated position.

10. The method of claim 1, for use in mode of administration (c), wherein the catheter has a distal end reservoir, the microparticles are contained as a particle suspension in the reservoir, and said injecting includes forcing the suspension out of the catheter through a catheter surface in contact with the vessel region.

11. The method of claim 10, wherein the particles are microbubbles containing the antisense compound is entrapped form, and the method further includes exposing the vessel region to ultrasonic energy following the particle injection.

12. The method of claim 1, for use in mode of administration (d), wherein the coating is designed to release the majority of the antisense compound in the coating over a period of 5-60 minutes following balloon angioplasty.

13. The method of claim 1, for use in mode of administration (e), wherein the stent is biodegradable, and is designed to release the majority of the antisense compound in the coating over a period of 5-60 minutes following balloon angioplasty.

14. A method of treating the risk of restenosis in a region of a patient'"'"'s coronary vessel, comprising

administering to the patient, by local delivery directly into the region of injury, a morpholino antisense compound having (i) the base sequence identified as SEQ ID NO:

1, and (ii) composed of uncharged phosphorodiamidate linkages interspersed with at least two and up to half positively charged phosphorodiamidate linkages, where the phosphorodiamidate linkages have the structure;

where Y₁=O, Z=O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide (where base-pairing moieties on different subunits may be the same or different), and X is alkyl, alkoxy, thioalkoxy, or alkyl amino of the form NR₂, where each R is independently hydrogen or methyl, for the uncharged linkages, and the positively charged linkages are represented by the same structure, but where X is 1-piperazino.

15. The method of claim 14, wherein the compound is derivatized with a moiety that enhances the solubility of the compound in aqueous medium, and the compound is administered from a solution containing at least about 30 mg/ml of the antisense compound.

16. A morpholino antisense compound having from 8 to 40 morpholino subunits (a) including a targeting base sequence that is complementary to a target sequence of at least 12 contiguous bases within the AUG start site region of human c-myc mRNA defined by SEQ ID NO:

2, and (b) that are linked by uncharged phosphorodiamidate linkages interspersed with at least two and up to half positively charged phosphorodiamidate linkages.

17. The compound of claim 16, wherein said morpholino subunits are joined by phosphorodiamidate linkages, in accordance with the structure:

20. The compound of claim 17, wherein the compound is derivatized with a moiety that enhances the solubility of the compound in aqueous medium, to a level of at least about 30 mg/ml of the antisense compound.

21. The compound of claim 20, wherein said moiety is triethyleneglycol attached to the 5′

end of the compound.

22. The compound of claim 17, which is entrapped in liposomal or biodegradable microparticles.

23. The compound of claim 17, which is carried as a coating on a stent.

18. (canceled)

19. (canceled)